We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Philips Sells MR-HIFU Business to Profound Medical

By MedImaging International staff writers
Posted on 15 Aug 2017
Royal Philips (Amsterdam, the Netherlands) has completed the sale of its Sonalleve MR-HIFU business to Profound Medical Inc. (Ontario, Canada).

Sonalleve MR-HIFU is an innovative therapeutic platform that combines real-time Magnetic Resonance Imaging (MRI) and thermometry with high intensity focused ultrasound to enable precise and incision-free ablation of diseased tissue. With the completion of this acquisition, Profound has become the only company to provide a therapeutics platform that provides the precision of real-time MRI combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue.

Image: The Sonalleve MR-HIFU system (Photo courtesy of Philips Healthcare).
Image: The Sonalleve MR-HIFU system (Photo courtesy of Philips Healthcare).

Philips will continue to distribute Profound’s TULSA-PRO system, which combines real-time MRI with transurethral, robotically driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects.

“We are excited about our enhanced close collaboration with Profound, as we aim to accelerate the development of new clinical applications and address the evolving needs of our current and future customers,” said Rob Cascella, Chief Business Leader Diagnosis and Treatment at Philips.

“This transaction with Philips is truly transformative for Profound, and represents an opportunity for us to immediately transition from a development-stage to a growth-stage company,” said Dr. Arun Menawat, Profound’s CEO. “From a commercial perspective, our strengthened MR-Ultrasound ablation technology platform not only benefits Profound by significantly increasing the total opportunity size and creating synergies, but also benefits hospital customers by providing them with the ability to better utilize their MR system assets. In addition to the contribution the acquisition of the Sonalleve MR-HIFU business will make to our revenue base, we believe that it will also help accelerate our growth going forward.”


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Digital Radiography Acquisition Software
VXvue with PureImpact
New
Thyroid Shield
Standard Thyroid Shield
New
Ultrasound Doppler System
Doppler BT-200

Latest Industry News News

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

International Societies Suggest Key Considerations for AI Radiology Tools